ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.

Timothy A Yap et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.